Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Zura Bio Limited - Class A Ordinary shares (ZURA)
Company Research
Source: Business Wire
Ended Q1 2024 with $89.8 million in cash and closed oversubscribed $112.5 million private placement in April 2024 from new and existing leading life sciences institutional investorsAppointed Robert Lisicki as CEO and Kiran Nistala, M.B.B.S., Ph.D. as CMOOn track to initiate Phase 2 studies evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025Projected cash runway extends support for operations through 2027 with the recent private placement factored in HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its first quarter 2024 financial results, and recent business highlights."Our recent financial and business highlights demonstrate how we continue to strengthen the company for future success. Our leadership additions and oversubscri
Show less
Read more
Impact Snapshot
Event Time:
ZURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZURA alerts
High impacting Zura Bio Limited - Class A Ordinary shares news events
Weekly update
A roundup of the hottest topics
ZURA
News
- Zura Bio Limited (NASDAQ: ZURA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $16.00 to $21.00. They now have an "outperform" rating on the stock.MarketBeat
- Zura Bio Limited (NASDAQ: ZURA) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $26.00 price target on the stock.MarketBeat
- Zura Bio Announces Oversubscribed $112.5 Million Private PlacementBusiness Wire
- Zura Bio Announces Robert Lisicki as CEO and DirectorBusiness Wire
- Zura Bio Limited (NASDAQ: ZURA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $16.00 price target on the stock, down previously from $17.00.MarketBeat
ZURA
Sec Filings
- 5/15/24 - Form 10-Q/A
- 5/9/24 - Form 8-K
- 5/9/24 - Form 10-Q
- ZURA's page on the SEC website